Global Incidence, Risk Factors, and Temporal Trends of Mesothelioma: A Population-Based Study

Journal of Thoracic Oncology, Journal Year: 2023, Volume and Issue: 18(6), P. 792 - 802

Published: Feb. 10, 2023

Mesothelioma is an uncommon type of cancer which has received little attention. This study aims to evaluate the global disease burden; trends mesothelioma by age, sex, and geographic locations; its risk factors on population level.The Global Cancer Observatory, Incidence in Five Continents Plus, Burden Disease were accessed for incidence worldwide. The associations between asbestos evaluated each country multivariable linear regression analysis sex age. Average annual percentage change (AAPC) was calculated using Joinpoint epidemiologic mesothelioma.The age-standardized rate 0.30 per 100,000 persons with Northern Europe reporting highest rates. male much higher than that females. Countries human development index (β = 0.119, confidence interval [CI]: 0.073-0.166, p < 0.001), gross domestic product capita 0.133, CI: 0.106-0.161, exposure 0.087, 0.073-0.102, 0.001) had mesothelioma. overall trend decreasing, although increase observed Bulgaria (AAPC: 5.56, 95% 2.94-8.24, Korea 3.24, 0.08-6.49, 0.045).There a substantial declining past decade possibly related restriction use some countries. Meanwhile, increasing females might be indicative environmental mineral fibers.

Language: Английский

---

Treatment of Pleural Mesothelioma: ASCO Guideline Update

Journal of Clinical Oncology, Journal Year: 2025, Volume and Issue: 43(8), P. 1006 - 1038

Published: Jan. 8, 2025

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following guideline development process as outlined in Methodology Manual . follow Conflict Interest Policy Clinical Practice other guidance (“Guidance”) provided by is not a or definitive guide to treatment options. It intended voluntary use clinicians should be used conjunction independent professional judgment. Guidance may applicable all patients, interventions, diseases stages diseases. based on analysis statement standard care. does endorse third-party drugs, devices, services, therapies assumes no responsibility any harm arising from related this information. See complete disclaimer Appendix 1 2 (online only) more PURPOSE To evidence-based practicing physicians others management pleural mesothelioma (PM). METHODS convened an Expert Panel medical oncology, thoracic surgery, radiation pathology, cancer genetics, advocacy experts conduct updated search, which included systematic reviews, meta-analyses, randomized controlled trials, prospective retrospective comparative observational studies published 2016 through 2024. Outcomes interest survival, disease-free recurrence-free quality life. members available evidence informal consensus develop recommendations. RESULTS The search identified 110 additional inform base guideline. RECOMMENDATIONS Evidence-based were developed surgical cytoreduction, immunotherapy, chemotherapy, germline testing patients PM. Additional information at www.asco.org/thoracic-cancer-guidelines

Language: Английский

---

BAP1 as a guardian of genome stability: implications in human cancer

Experimental & Molecular Medicine, Journal Year: 2023, Volume and Issue: 55(4), P. 745 - 754

Published: April 3, 2023

Abstract BAP1 is a ubiquitin C-terminal hydrolase domain-containing deubiquitinase with wide array of biological activities. Studies in which advanced sequencing technologies were used have uncovered link between and human cancer. Somatic germline mutations the gene been identified multiple cancers, particularly high frequency mesothelioma, uveal melanoma clear cell renal carcinoma. cancer syndrome highlights that all carriers inherited -inactivating develop at least one often cancers penetrance during their lifetime. These findings, together substantial evidence indicating involvement many cancer-related activities, strongly suggest functions as tumor suppressor. Nonetheless, mechanisms account for suppressor function only begun to be elucidated. Recently, roles genome stability apoptosis drawn considerable attention, they are compelling candidates key mechanistic factors. In this review, we focus on summarize details cellular molecular DNA repair replication, crucial integrity, discuss implications BAP1-associated relevant therapeutic strategies. We also highlight some unresolved issues potential future research directions.

Language: Английский

---

Guidelines for Pathologic Diagnosis of Mesothelioma

Archives of Pathology & Laboratory Medicine, Journal Year: 2024, Volume and Issue: 148(11), P. 1251 - 1271

Published: April 8, 2024

Context.— Mesothelioma is an uncommon tumor that can be difficult to diagnose. Objective.— To provide updated, practical guidelines for the pathologic diagnosis of mesothelioma. Data Sources.— Pathologists involved in International Interest Group and others with expertise mesothelioma contributed this update. Reference material includes peer-reviewed publications textbooks. Conclusions.— There was consensus opinion regarding (1) histomorphologic mesothelial tumors, including distinction epithelioid, biphasic, sarcomatoid mesothelioma; recognition morphologic variants patterns; common pitfalls; (2) molecular pathogenesis (3) application immunohistochemical markers establish lineage distinguish from differentials; (4) ancillary studies benign malignant proliferations, BAP1 MTAP immunostains; novel immunomarkers such as Merlin p53; fluorescence situ hybridization (FISH) homozygous deletion CDKN2A; assays; (5) recommendations routine reporting mesothelioma, grading epithelioid other prognostic parameters; (6) situ; (7) cytologic use immunostains (8) features nonmalignant peritoneal lesions.

Language: Английский

---

Cytoreductive surgery in diffuse pleural mesothelioma. What have we learnt from MARS2, EORTC-L1205 and other recent studies?

European Journal of Surgical Oncology, Journal Year: 2025, Volume and Issue: unknown, P. 109628 - 109628

Published: Jan. 1, 2025

Language: Английский

---

Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights

JCO Oncology Practice, Journal Year: 2025, Volume and Issue: unknown

Published: March 7, 2025

Language: Английский

---

Defining and targeting tumor-associated macrophages in malignant mesothelioma

Proceedings of the National Academy of Sciences, Journal Year: 2023, Volume and Issue: 120(9)

Published: Feb. 23, 2023

Defining the ontogeny of tumor-associated macrophages (TAM) is important to develop therapeutic targets for mesothelioma. We identified two distinct macrophage populations in mouse peritoneal and pleural cavities, monocyte-derived, small peritoneal/pleural (SPM), tissue-resident large (LPM). SPM rapidly increased tumor microenvironment after challenge contributed vast majority M2-like TAM. The selective depletion TAM by conditional deletion Dicer1 gene myeloid cells (D −/− ) promoted rejection. Sorted initiated tumorigenesis vivo vitro, confirming their capacity support development. transcriptomic single-cell RNA sequencing analysis demonstrated that both LPM promoting IL-2-STAT5 signaling pathway, inflammation, epithelial–mesenchymal transition. However, while preferentially activated KRAS TNF-α/NFkB pathways, IFN-γ response. importance immune response was confirmed depleting with intrapleural clodronate liposomes, which abrogated antitumoral memory immunity. signature could be effusion from patients untreated Five genes, TREM2, STAB1, LAIR1, GPNMB , MARCO potentially specific targets. Accordingly, Trem2 led reduced compensatory increase slower growth. Overall, these experiments demonstrate play a key role mesothelioma development, more specifically contribute Therefore, targeting monocyte-derived may enhance antitumor immunity through expansion

Language: Английский

---

Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome

European Journal of Human Genetics, Journal Year: 2023, Volume and Issue: 31(11), P. 1261 - 1269

Published: Aug. 22, 2023

Abstract BRCA1-associated protein-1 (BAP1) is a recognised tumour suppressor gene. Germline BAP1 pathogenic/likely pathogenic variants are associated with predisposition to multiple tumours, including uveal melanoma, malignant pleural and peritoneal mesothelioma, renal cell carcinoma specific non-malignant neoplasms of the skin, as part autosomal dominant -tumour syndrome. The overall lifetime risk for carriers develop at least one -associated up 85%, although due ascertainment bias, current estimates likely be overestimated. As many rare cancer syndromes, there limited scientific evidence support utility surveillance and, therefore, management recommendations based on expert opinion. To date, European have not been published but necessary emerging phenotype this recently described syndrome increased identification via large gene panels or sequencing. address this, Clinical Guideline Working Group CanGene-CanVar project in United Kingdom invited collaborators collaborate guidelines harmonize programmes within Europe. Recommendations respect testing were achieved following literature review Delphi survey completed by core group an extended 34 specialists Geneticists, Ophthalmologists, Oncologists, Dermatologists Pathologists. It that these largely evidence-based pragmatic will evolve over time further data from research collaborations informs phenotypic spectrum outcomes.

Language: Английский

---

BAP1 is a novel regulator of HIF-1α

Proceedings of the National Academy of Sciences, Journal Year: 2023, Volume and Issue: 120(4)

Published: Jan. 19, 2023

BAP1 is a powerful tumor suppressor gene characterized by haplo insufficiency. Individuals carrying germline mutations often develop mesothelioma, an aggressive malignancy of the serosal layers covering lungs, pericardium, and abdominal cavity. Intriguingly, mesotheliomas developing in carriers are less aggressive, these patients have significantly improved survival. We investigated apparent paradox that, when mutated, causes mesotheliomas. discovered that mesothelioma biopsies with biallelic showed loss nuclear HIF-1α staining. demonstrated during hypoxia, binds, deubiquitylates, stabilizes HIF-1α, master regulator hypoxia response cell invasion. Moreover, primary cells from individuals which was silenced using siRNA had reduced protein levels hypoxia. Computational modeling co-immunoprecipitation experiments revealed residues I675, F678, I679, L691 -encompassing C-terminal domain-nuclear localization signal- to A, abolished interaction HIF-1α. found binds N-terminal region where DNA dimerizes HIF-1β forming heterodimeric transactivating complex HIF. Our data identify as key positive propose significant reduction activity mutations, accompanied hypoxic tissues containing contributes aggressiveness survival mutations.

Language: Английский

---

Did the Ban on Asbestos Reduce the Incidence of Mesothelioma?

Journal of Thoracic Oncology, Journal Year: 2023, Volume and Issue: 18(6), P. 694 - 697

Published: May 18, 2023

Language: Английский

---